Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. MGC Pharmaceuticals Limited
  6. News
  7. Press Releases
    MXC   AU000000MXC6

MGC PHARMACEUTICALS LIMITED

(MXC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société MGC PHARMACEUTICALS LIMITED
01/13MGC PHARMACEUTICALS : General Meeting Notice of Meeting
PU
2021MGC PHARMACEUTICALS : Application for quotation of securities - MXC
PU
2021MGC PHARMACEUTICALS : Application for quotation of securities - MXC
PU
2021Notification regarding unquoted securities - MXC
PU
2021MGC PHARMACEUTICALS : Proposed issue of Securities - MXC
PU
2021MGC PHARMACEUTICALS : Change of Company Secretary, Perf Rights & Remuneration
PU
2021MGC PHARMACEUTICALS : Mxc completes first artemic order, march qtr record revenue
PU
2021MGC PHARMACEUTICALS : Ethics Committee Approval Granted Phase III Clinical Trial
PU
2021MGC PHARMACEUTICALS : Pharma General Meeting Information and Webinar
PU
2021MGC PHARMACEUTICALS : Pharma Welcomes Admission to the LSE
PU
2020MGC PHARMACEUTICALS : Pharma to receive grant for Malta production facility
PU
2020MGC PHARMACEUTICALS : ArtemiC Phase II Clinical Trial Results
PU
2020MGC PHARMACEUTICALS : Completion of Unmarketable Parcel Share Sale Facility
PU
2020MGC PHARMACEUTICALS : ArtemiC Phase II Clinical Trial Results Update
PU
2020MGC PHARMACEUTICALS : Pharma to benefit from UN vote to reschedule Cannabis
PU
2020MGC PHARMACEUTICALS : Amended MGC Nutraceuticals Sales Update
PU
2020MGC PHARMACEUTICALS : Nutraceuticals Sale Update
PU
2020MGC PHARMACEUTICALS : Company Secretary Appointment
PU
2020MGC PHARMACEUTICALS : Issue of Securities - Appendix 2A
PU
2020MGC PHARMACEUTICALS : Proposed issue of Securities - MXC
PU
2020MGC PHARMACEUTICALS : Prospectus
PU
2020MGC PHARMACEUTICALS : Drawdown of $3.5m Convertible Note
PU
2020MGC PHARMACEUTICALS : Pharma completes acquisition of telehealth platform mcc
PU
2020MGC PHARMACEUTICALS : Further successful results from glioblastoma research
PU
2020MGC PHARMACEUTICALS : Conversion of Convertible Notes - Appendix 2A
PU
2020MGC PHARMACEUTICALS : Completion of phase ii clinical trial on covid-19 patients
PU
2020MGC PHARMACEUTICALS : Results of Annual General Meeting
PU
2020MGC PHARMACEUTICALS : Constitution
PU
2020MGC PHARMACEUTICALS : AGM Presentation
PU
2020MGC PHARMACEUTICALS : Annual Report 2020
PU
2020MGC PHARMACEUTICALS : September Quarterly Activity and Cashflow Report
PU
2020MGC PHARMACEUTICALS : Unmarketable Parcel Share Sale Update
PU
2020MGC PHARMACEUTICALS : Artemic histology on rats confirm no pathological impact
PU
2020MGC PHARMACEUTICALS : First high thc products shipped direct to brazil patients
PU
2020MGC PHARMACEUTICALS : Pharma launches cannepil app
PU
2020MGC PHARMACEUTICALS : Notice of Annual General Meeting/Proxy Form
PU
2020MGC PHARMACEUTICALS : Annual Report for the year ended 30 June 2020
PU
2020MGC PHARMACEUTICALS : Appendix 4G and Corporate Governance Statement
PU
2020MGC PHARMACEUTICALS : Update on artemic phase ii trial on covid-19 patients
PU
2020MGC PHARMACEUTICALS : Mxc welcomes new fca guidance for cannabis sector in the uk
PU
2020MGC PHARMACEUTICALS : Issue of Securities - Appendix 2A
PU
2020MGC PHARMACEUTICALS : Mxc well positioned for tga down-schedule of cbd products
PU
2020MGC PHARMACEUTICALS : Prospectus
PU
2020MGC PHARMACEUTICALS : $15m finance facility to fund revenue growth for key markets
PU
2020MGC PHARMACEUTICALS : Proposed issue of Securities - MXC
PU
2020MGC PHARMACEUTICALS : Trading Halt
PU
2020MGC PHARMACEUTICALS : Biopharma appointments strengthen board and leadership team
PU
2020MGC PHARMACEUTICALS : Appendix 4E and Preliminary Unaudited Financial Report
PU
2020MGC PHARMACEUTICALS : COVID-19 Interim Trial Results Meet All Primary Objectives
PU
2020MGC PHARMACEUTICALS : Trading Halt
PU
2020MGC PHARMACEUTICALS : Uk distribution agreement signed for mgc pharma medicines
PU
2020MGC PHARMACEUTICALS : Change of Director's Interest Notice - Appendix 3Y x 2
PU
2020MGC PHARMACEUTICALS : Issue of Securities
PU
2020MGC PHARMACEUTICALS : Prospectus
PU
2020MGC PHARMACEUTICALS : Issue of Securities - Appendix 2A
PU
2020MGC PHARMACEUTICALS : Proposed issue of Securities - MXC
PU
2020MGC PHARMACEUTICALS : Study confirms effectiveness of artemic on human immune cell
PU
2020MGC PHARMACEUTICALS : Trading halt
PU
2020MGC PHARMACEUTICALS : Pause in trading
PU
2020MGC PHARMACEUTICALS : Appendix 2A - Exercise of MXCOE Options
PU
2020MGC PHARMACEUTICALS : June Quarterly Activity and Cashflow Report
PU
2020MGC PHARMACEUTICALS : Reinstatement to Official Quotation
PU
2020MGC PHARMACEUTICALS : Results from ArtemiC Safety and Toxicity Pre-clinical Study
PU
2020MGC PHARMACEUTICALS : Suspension from Official Quotation
PU
2020MGC PHARMACEUTICALS : Results of General Meeting
PU
2020MGC PHARMACEUTICALS : COVID-19 Clinical Trial Site Expansion into India
PU
2020MGC PHARMACEUTICALS : Pharma GM Webinar
PU
2020MGC PHARMACEUTICALS : MXC Awarded 3-year EU GMP Manufacturing Licence
PU
2020MGC PHARMACEUTICALS : 3,250 Prescriptions Milestone Surpassed
PU
2020MGC PHARMACEUTICALS : Ethics Committee Approval for CannEpil Phase IIb Trial
PU
2020MGC PHARMACEUTICALS : Binding Term Sheet Signed for Distribution of ArtemiC
PU
2020MGC PHARMACEUTICALS : Reinstatement to Official Quotation
PU
2020MGC PHARMACEUTICALS : Extension of Voluntary Suspension
PU
2020MGC PHARMACEUTICALS : Voluntary Suspension
PU
2020MGC PHARMACEUTICALS : Pause in Trading
PU
1  2  3Next
Upcoming event on MGC PHARMACEUTICALS LIMITED